GLMD
Galmed Pharmaceuticals Ltd.
Price Chart
Latest Quote
$0.55
-0.00 (-0.76%)
Current Price
| Previous Close | $0.55 |
| Open | $0.53 |
| Day High | $0.59 |
| Day Low | $0.52 |
| Volume | 315,420 |
Stock Information
| Shares Outstanding | 7.68M |
| Cash Equivalents | $15.45M |
| Net Income | $-11.12M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $4.19M |
| EPS (TTM) | $-2.06 |
| Exchange | NCM |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $-11.85M |
| Income | $-11.12M |
| Book/sh | $2.11 |
| Cash/sh | $2.01 |
| Employees | 3 |
Financial Ratios
| Quick Ratio | 7.65 |
| Current Ratio | 7.71 |
Returns & Margins
| ROA | -33.46% |
| ROE | -72.12% |
Ownership
| Insider Ownership | 3.30% |
| Institutional Ownership | 1.92% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | -0.53 |
| P/B | 0.26 |
Analyst Data
| Recommendation | none |
Technical Indicators
| SMA20 | $0.56 |
| SMA50 | $0.60 |
| SMA200 | $0.81 |
| RSI | 45.57 |
| ATR | 0.0566 |
| Shares Float | 6.39M |
| Short Float | 0.99% |
| Short Ratio | 0.06 |
| Volatility | 0.74 |
| Rel Volume | 0.38 |
Performance History
| Week | -2.50% |
| Month | -9.60% |
| Quarter | -26.12% |
| 6 Months | -33.66% |
| YTD | -33.66% |
| Year | -75.07% |
| 3 Years | -98.13% |
| 5 Years | -99.90% |
| 10 Years | -99.93% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-07-17 | $0.55 | 316,300 |
| 2026-07-16 | $0.55 | 14,147,300 |
| 2026-07-15 | $0.51 | 20,900 |
| 2026-07-14 | $0.51 | 27,700 |
| 2026-07-13 | $0.54 | 67,700 |
| 2026-07-10 | $0.56 | 25,400 |
| 2026-07-09 | $0.57 | 15,300 |
| 2026-07-08 | $0.57 | 41,500 |
| 2026-07-07 | $0.57 | 56,800 |
| 2026-07-06 | $0.56 | 37,700 |
| 2026-07-02 | $0.57 | 107,200 |
| 2026-07-01 | $0.65 | 707,700 |
| 2026-06-30 | $0.56 | 26,100 |
| 2026-06-29 | $0.57 | 62,100 |
| 2026-06-26 | $0.57 | 26,100 |
| 2026-06-25 | $0.57 | 110,000 |
| 2026-06-24 | $0.59 | 65,900 |
| 2026-06-23 | $0.57 | 37,600 |
| 2026-06-22 | $0.56 | 755,200 |
| 2026-06-18 | $0.58 | 47,300 |
About Galmed Pharmaceuticals Ltd.
Galmed Pharmaceuticals Ltd., a biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases and related indications. The company develops Aramchol, a first-in-class synthetic fatty acid-bile acid conjugate molecule which is in a Phase III study for oral treatment for non-alcoholic steato-hepatitis (NASH) in patients who are overweight or obese and have prediabetes or type II diabetes mellitus. The company also evaluates Aramchol through the ARRIVE Study, a Phase IIa clinical trial with HIV-associated non-alcoholic fatty liver disease and lipodystrophy. In addition, it engages in the development of Amilo-5MER, a 5 amino acid synthetic peptide methionine, threonine, alanine, aspartic acid, and valine. Further, the company is developing MyBiotics, which is in pre-clinical trials for NASH and fibrosis. It has a license agreement with Samil Pharma. Co., Ltd. for the commercialization of Aramchol in the Republic of Korea; and a collaboration agreement with OnKai for its AI platform and Tissue Dynamics to develop a novel human chronic cardiac fibrosis model. Galmed Pharmaceuticals Ltd. was founded in 2000 and is headquartered in Ramat Gan, Israel.
đ° Latest News
Galmed Develops Cardiac-Targeted Aramchol Formulation to Expand Cardiovascular Pipeline (NASDAQ:GLMD)
InvestorsHub âĸ 2026-07-16T14:05:26Z
Galmed Pharmaceuticals: Q3 Earnings Snapshot
Associated Press Finance âĸ 2025-11-26T13:56:35ZBC-Most Active Stocks
Associated Press Finance âĸ 2025-11-17T15:30:18ZGalmed Pharmaceuticals: Q2 Earnings Snapshot
Associated Press Finance âĸ 2025-08-28T12:08:56Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Total Revenue | $0 | $0 | $0 | $0 |
| Operating Revenue | $0 | $0 | $0 | $0 |
| Expenses | ||||
| Total Expenses | $8,510,000 | $6,278,000 | $7,492,000 | $17,651,000 |
| Rent Expense Supplemental | $34,000 | $117,000 | $261,000 | $401,000 |
| Other Income Expense | $-2,618,000 | $-1,117,000 | $216,000 | $-490,000 |
| Net Non Operating Interest Income Expense | $819,000 | $-122,000 | $364,000 | $275,000 |
| Total Other Finance Cost | $95,000 | $625,000 | $11,000 | $22,000 |
| Operating Expense | $8,510,000 | $6,278,000 | $7,492,000 | $17,651,000 |
| General And Administrative Expense | $3,636,000 | $3,299,000 | $3,923,000 | $4,656,000 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-10,309,000 | $-7,517,000 | $-6,912,000 | $-17,866,000 |
| Net Interest Income | $819,000 | $-122,000 | $364,000 | $275,000 |
| Interest Income | $914,000 | $503,000 | $375,000 | $297,000 |
| Normalized Income | $-7,691,000 | $-6,400,000 | $-7,128,000 | $-17,376,000 |
| Net Income From Continuing And Discontinued Operation | $-10,309,000 | $-7,517,000 | $-6,912,000 | $-17,866,000 |
| Total Operating Income As Reported | $-8,510,000 | $-6,278,000 | $-7,492,000 | $-17,651,000 |
| Net Income Common Stockholders | $-10,309,000 | $-7,517,000 | $-6,912,000 | $-17,866,000 |
| Net Income | $-10,309,000 | $-7,517,000 | $-6,912,000 | $-17,866,000 |
| Net Income Including Noncontrolling Interests | $-10,309,000 | $-7,517,000 | $-6,912,000 | $-17,866,000 |
| Net Income Continuous Operations | $-10,309,000 | $-7,517,000 | $-6,912,000 | $-17,866,000 |
| Pretax Income | $-10,309,000 | $-7,517,000 | $-6,912,000 | $-17,866,000 |
| Special Income Charges | $-2,461,000 | $-1,145,000 | $0 | $0 |
| Interest Income Non Operating | $914,000 | $503,000 | $375,000 | $297,000 |
| Operating Income | $-8,510,000 | $-6,278,000 | $-7,492,000 | $-17,651,000 |
| Per Share | ||||
| Diluted EPS | $-2.39 | $-8.08 | $-30.00 | $-127.80 |
| Basic EPS | $-2.39 | $-8.08 | $-30.00 | $-127.80 |
| Other | ||||
| Tax Effect Of Unusual Items | $0 | $0 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-5,892,000 | $-5,078,000 | $-7,677,000 | $-17,126,000 |
| Total Unusual Items | $-2,618,000 | $-1,117,000 | $216,000 | $-490,000 |
| Total Unusual Items Excluding Goodwill | $-2,618,000 | $-1,117,000 | $216,000 | $-490,000 |
| Reconciled Depreciation | $0 | $83,000 | $31,000 | $35,000 |
| EBITDA (Bullshit earnings) | $-8,510,000 | $-6,195,000 | $-7,461,000 | $-17,616,000 |
| EBIT | $-8,510,000 | $-6,278,000 | $-7,492,000 | $-17,651,000 |
| Diluted Average Shares | $4,311,323 | $930,822 | $230,795 | $139,682 |
| Basic Average Shares | $4,311,323 | $930,822 | $230,795 | $139,682 |
| Diluted NI Availto Com Stockholders | $-10,309,000 | $-7,517,000 | $-6,912,000 | $-17,866,000 |
| Write Off | $2,461,000 | $1,145,000 | $0 | $0 |
| Gain On Sale Of Security | $-157,000 | $28,000 | $216,000 | $-490,000 |
| Research And Development | $4,874,000 | $2,979,000 | $3,569,000 | $12,995,000 |
| Selling General And Administration | $3,636,000 | $3,299,000 | $3,923,000 | $4,656,000 |
| Other Gand A | $899,000 | $896,000 | $908,000 | $1,084,000 |
| Insurance And Claims | $378,000 | $389,000 | $677,000 | $1,094,000 |
| Rent And Landing Fees | $34,000 | $117,000 | $261,000 | $401,000 |
| Salaries And Wages | $2,325,000 | $1,897,000 | $2,077,000 | $2,077,000 |
Fetched: 2026-07-07
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $15,782,000 | $16,327,000 | $13,879,000 | $13,423,000 |
| Total Assets | $18,627,000 | $18,500,000 | $16,629,000 | $16,561,000 |
| Total Non Current Assets | $0 | $2,376,000 | $3,390,000 | $1,837,000 |
| Non Current Note Receivables | $0 | $257,000 | $0 | - |
| Current Assets | $18,627,000 | $16,124,000 | $13,239,000 | $14,724,000 |
| Restricted Cash | $124,000 | $121,000 | $117,000 | $114,000 |
| Prepaid Assets | $267,000 | $463,000 | $315,000 | $668,000 |
| Receivables | $80,000 | $209,000 | $165,000 | $157,000 |
| Other Receivables | $80,000 | $209,000 | $165,000 | $157,000 |
| Cash Cash Equivalents And Short Term Investments | $18,156,000 | $15,331,000 | $12,642,000 | $13,785,000 |
| Cash And Cash Equivalents | $3,985,000 | $4,652,000 | $2,861,000 | $2,016,000 |
| Investmentin Financial Assets | - | - | $0 | $1,500,000 |
| Debt | ||||
| Total Debt | - | $0 | $41,000 | $215,000 |
| Long Term Debt And Capital Lease Obligation | - | - | $0 | $44,000 |
| Current Debt And Capital Lease Obligation | - | - | $41,000 | $171,000 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $2,845,000 | $2,173,000 | $2,750,000 | $3,138,000 |
| Total Non Current Liabilities Net Minority Interest | $0 | $0 | $0 | $44,000 |
| Current Liabilities | $2,845,000 | $2,173,000 | $2,750,000 | $3,094,000 |
| Payables And Accrued Expenses | $2,288,000 | $1,570,000 | $2,138,000 | $2,763,000 |
| Payables | $2,005,000 | $1,314,000 | $1,879,000 | $2,567,000 |
| Other Payable | $2,000 | $6,000 | - | $7,000 |
| Accounts Payable | $2,003,000 | $1,308,000 | $1,879,000 | $2,560,000 |
| Equity | ||||
| Common Stock Equity | $15,782,000 | $16,327,000 | $13,879,000 | $13,423,000 |
| Total Equity Gross Minority Interest | $15,782,000 | $16,327,000 | $13,879,000 | $13,423,000 |
| Stockholders Equity | $15,782,000 | $16,327,000 | $13,879,000 | $13,423,000 |
| Gains Losses Not Affecting Retained Earnings | $-303,000 | $-416,000 | $-454,000 | $-745,000 |
| Other Equity Adjustments | $-303,000 | $-416,000 | $-454,000 | $-745,000 |
| Retained Earnings | $-210,778,000 | $-200,469,000 | $-192,952,000 | $-186,040,000 |
| Long Term Equity Investment | $0 | $2,119,000 | $3,265,000 | $0 |
| Other | ||||
| Ordinary Shares Number | $6,581,390 | $1,664,884 | $420,443 | $140,018 |
| Share Issued | $6,581,390 | $1,664,884 | $420,443 | $140,018 |
| Tangible Book Value | $15,782,000 | $16,327,000 | $13,879,000 | $13,423,000 |
| Invested Capital | $15,782,000 | $16,327,000 | $13,879,000 | $13,423,000 |
| Working Capital | $15,782,000 | $13,951,000 | $10,489,000 | $11,630,000 |
| Total Capitalization | $15,782,000 | $16,327,000 | $13,879,000 | $13,423,000 |
| Additional Paid In Capital | $223,455,000 | $216,470,000 | $207,076,000 | $200,138,000 |
| Capital Stock | $3,408,000 | $742,000 | $209,000 | $70,000 |
| Common Stock | $3,408,000 | $742,000 | $209,000 | $70,000 |
| Pensionand Other Post Retirement Benefit Plans Current | $557,000 | $603,000 | $571,000 | $160,000 |
| Current Accrued Expenses | $283,000 | $256,000 | $259,000 | $196,000 |
| Investments And Advances | $0 | $2,119,000 | $3,265,000 | $1,500,000 |
| Investmentsin Associatesat Cost | $0 | $2,119,000 | $3,265,000 | $0 |
| Other Short Term Investments | $14,171,000 | $10,679,000 | $9,781,000 | $11,769,000 |
| Capital Lease Obligations | - | $0 | $41,000 | $215,000 |
| Current Capital Lease Obligation | - | $0 | $41,000 | $171,000 |
| Net PPE | - | $0 | $125,000 | $337,000 |
| Accumulated Depreciation | - | $-1,103,000 | $-1,019,000 | $-988,000 |
| Gross PPE | - | $1,103,000 | $1,144,000 | $1,325,000 |
| Leases | - | $236,000 | $235,000 | $235,000 |
| Other Properties | - | $737,000 | $779,000 | $960,000 |
| Machinery Furniture Equipment | - | $130,000 | $130,000 | $130,000 |
| Properties | - | $0 | $0 | $0 |
| Long Term Capital Lease Obligation | - | - | $0 | $44,000 |
| Available For Sale Securities | - | - | - | $1,500,000 |
Fetched: 2026-07-07
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-6,315,000 | $-5,880,000 | $-6,137,000 | $-18,505,000 |
| Operating Activities | ||||
| Operating Cash Flow | $-6,315,000 | $-5,880,000 | $-6,137,000 | $-18,501,000 |
| Cash Flow From Continuing Operating Activities | $-6,315,000 | $-5,880,000 | $-6,137,000 | $-18,501,000 |
| Operating Gains Losses | $81,000 | $12,000 | $13,000 | $523,000 |
| Investing Activities | ||||
| Investing Cash Flow | $-3,375,000 | $-1,111,000 | $800,000 | $17,563,000 |
| Cash Flow From Continuing Investing Activities | $-3,375,000 | $-1,111,000 | $800,000 | $17,563,000 |
| Net Other Investing Changes | - | $-250,000 | - | - |
| Capital Expenditure | - | - | - | $-4,000 |
| Financing Activities | ||||
| Issuance Of Capital Stock | $9,026,000 | $8,786,000 | $6,185,000 | $70,000 |
| Financing Cash Flow | $9,026,000 | $8,786,000 | $6,185,000 | $70,000 |
| Cash Flow From Continuing Financing Activities | $9,026,000 | $8,786,000 | $6,185,000 | $70,000 |
| Net Common Stock Issuance | $9,026,000 | $8,786,000 | $6,185,000 | $70,000 |
| Common Stock Issuance | $9,026,000 | $8,786,000 | $6,185,000 | $70,000 |
| Other | ||||
| End Cash Position | $4,109,000 | $4,773,000 | $2,978,000 | $2,130,000 |
| Beginning Cash Position | $4,773,000 | $2,978,000 | $2,130,000 | $2,998,000 |
| Changes In Cash | $-664,000 | $1,795,000 | $848,000 | $-868,000 |
| Net Investment Purchase And Sale | $-3,375,000 | $-861,000 | $2,300,000 | $17,567,000 |
| Sale Of Investment | $1,611,000 | $5,504,000 | $8,633,000 | $21,440,000 |
| Purchase Of Investment | $-4,986,000 | $-6,365,000 | $-6,333,000 | $-3,873,000 |
| Net Business Purchase And Sale | $0 | $0 | $-1,500,000 | $0 |
| Purchase Of Business | $0 | $0 | $-1,500,000 | $0 |
| Change In Working Capital | $912,000 | $-728,000 | $132,000 | $-2,451,000 |
| Change In Payables And Accrued Expense | $672,000 | $-536,000 | $-213,000 | $-2,751,000 |
| Change In Payable | $672,000 | $-536,000 | $-213,000 | $-2,751,000 |
| Change In Account Payable | $695,000 | $-571,000 | $-681,000 | $-2,311,000 |
| Change In Receivables | $240,000 | $-192,000 | $345,000 | $300,000 |
| Other Non Cash Items | $-21,000 | $611,000 | $-47,000 | $-36,000 |
| Stock Based Compensation | $546,000 | $531,000 | $892,000 | $1,296,000 |
| Unrealized Gain Loss On Investment Securities | $0 | $0 | $-265,000 | $0 |
| Asset Impairment Charge | $2,461,000 | $1,145,000 | $0 | $0 |
| Amortization Of Securities | $15,000 | $-17,000 | $19,000 | $-2,000 |
| Depreciation Amortization Depletion | $0 | $83,000 | $31,000 | $35,000 |
| Depreciation And Amortization | $0 | $83,000 | $31,000 | $35,000 |
| Depreciation | $0 | $83,000 | $31,000 | $35,000 |
| Gain Loss On Investment Securities | $81,000 | $12,000 | $13,000 | $523,000 |
| Net Income From Continuing Operations | $-10,309,000 | $-7,517,000 | $-6,912,000 | $-17,866,000 |
| Net PPE Purchase And Sale | - | $0 | $0 | $-4,000 |
| Purchase Of PPE | - | $0 | $0 | $-4,000 |
| Change In Other Working Capital | - | $7,000 | $-53,000 | - |
| Earnings Losses From Equity Investments | - | $-7,000 | $0 | $0 |
| Proceeds From Stock Option Exercised | - | - | $0 | $0 |
Fetched: 2026-07-07